Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
IPNSAE
1 other identifier
observational
600
1 country
1
Brief Summary
This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 17, 2019
CompletedFirst Posted
Study publicly available on registry
May 21, 2019
CompletedStudy Start
First participant enrolled
May 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2019
CompletedMay 21, 2019
May 1, 2019
Same day
May 17, 2019
May 17, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.
Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.
3 years
Secondary Outcomes (2)
Location (city) of diagnosis
1 hour
French general population of each counties
3 years
Study Arms (1)
Paraneoplastic neurological syndromes patients
Patients tested for Paraneoplastic neurological syndromes (PNS) and Autoimmune Encephalitis (AE) with a lumbar puncture, with detection of an antibody or negative, but with PNS clinically diagnosed.
Eligibility Criteria
Patients diagnosed with a paraneoplastic neurological syndrome or autoimmune encephalitis in France and referred to the national center in Lyon between 2016 and 2018.
You may qualify if:
- \- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018
You may not qualify if:
- Data on location of diagnosis missing
- Patients diagnosed out of the mainland French territory
- Patients for whom insufficient data was available
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, 69003, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jérôme Honnorat
center for paraneoplastic neurological syndromes and autoimmune encephalitis
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 17, 2019
First Posted
May 21, 2019
Study Start
May 30, 2019
Primary Completion
May 30, 2019
Study Completion
July 31, 2019
Last Updated
May 21, 2019
Record last verified: 2019-05